Risk Factors for Kala-Azar in Bangladesh by Bern, Caryn et al.
Since 1990, South Asia has experienced a resurgence
of kala-azar (visceral leishmaniasis). To determine risk fac-
tors for kala-azar, we performed cross-sectional surveys
over a 3-year period in a Bangladeshi community. By histo-
ry, active case detection, and serologic screening, 155 of
2,356 residents had kala-azar with onset from 2000 to
2003. Risk was highest for persons 3–45 years of age, and
no significant difference by sex was seen. In age-adjusted
multivariable models, 3 factors were identified: proximity to
a previous kala-azar patient (odds ratio [OR] 25.4, 95%
confidence interval [CI] 15–44 within household; OR 3.2
95% CI 1.7–6.1 within 50 m), bed net use in summer (OR
0.7, 95% CI 0.53–0.93), and cattle per 1,000 m2 (OR 0.8,
95% CI 0.70–0.94]). No difference was seen by income,
education, or occupation; land ownership or other assets;
housing materials and condition; or keeping goats or chick-
ens inside bedrooms. Our data confirm strong clustering
and suggest that insecticide-treated nets could be effective
in preventing kala-azar.
S
ince 1990, South Asia has experienced a resurgence of
the lethal parasitic disease visceral leishmaniasis (VL).
India, Bangladesh, and Nepal account for an estimated
300,000 cases annually and 60% of the global burden (in
terms of disability-adjusted life years lost) of VL (1,2).
Superimposed on this poorly controlled VL-endemic situ-
ation are outbreaks that affect hundreds of thousands of
people, as in Bihar in the early 1990s (3). The full-blown
clinical syndrome caused by VL is characterized by fever,
weight loss, splenomegaly, hepatomegaly, skin darkening,
and anemia and is known as kala-azar (“black fever” in
Hindi). Kala-azar is nearly always fatal if untreated (4).
Even with treatment, case-fatality rates often exceed 10%
in VL-endemic areas of Asia and Africa (5).
Leishmania donovani is transmitted by the female sand
fly, and humans are the only reservoir in South Asia (6).
Blanket residual insecticide spraying decreased the inci-
dence of kala-azar below detectable levels in India and
Bangladesh by the 1960s (3), which suggests that sus-
tained vector control could substantially reduce disease
prevalence today. Efforts to control this neglected disease
have recently gained momentum from the government of
India’s commitment to eliminate kala-azar by the year
2010 (7). Nevertheless, data on the epidemiology of
anthroponotic VL are sparse. To plan effective strategies
for VL control and elimination, we must understand pat-
terns of disease occurrence both at the community level
and at broader geographic and ecologic levels. To elucidate
the determinants at the community level, we studied spa-
tial patterns and risk factors for kala-azar in a highly
affected community in Bangladesh. 
Methods
The study design was based on cross-sectional house-
hold surveys from January to April in 2002, 2003, and 2004.
The surveys included leishmaniasis serologic studies and
active kala-azar case detection. The study physician (M.A.)
was present during the surveys and at regular intervals
between surveys and offered free diagnosis for residents
with suspected kala-azar; thus, additional ascertainment
occurred between surveys. The protocol was approved by
the International Centre for Diarrhoeal Disease Research,
Bangladesh (ICDDR,B) Research and Ethical Review
Committees and the Institutional Review Board of the
Centers for Disease Control and Prevention (CDC).
Informed consent was obtained from all adult participants
and a parent or guardian of all participating children. Assent
was also obtained from children >7 years of age. 
The study community is located in Fulbaria Thana,
Mymensingh District, the “thana” (subdistrict) that has
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Bangladesh since 2000. Community members identified
the seasons as winter (October 15–March 15), summer
(March 15–June 15), and rainy season (June 15–October
15). The community houses ≈12,000 people and is divided
into 9 “paras” (sections) of ≈100 to 500 households. The
paras are separated by 1 to 2 km and physically are much
like separate villages, but politically they are considered
parts of the same community. The study area comprised
the 3 paras with the highest kala-azar rates during the pre-
vious several years according to villagers’ reports; these
were designated paras 1–3 (8). The study included all
members living in the study area for >6 months in the 3
years before the 2002 survey. Household questionnaires
were used to collect data on births, deaths, inward and out-
ward migration, socioeconomic factors, animal ownership,
and house construction. Individual questionnaires focused
on sleeping location, bed net use, and dietary practices.
Kala-Azar Case Ascertainment
During the 2002 survey, we attempted to retrospective-
ly identify all kala-azar cases that had occurred in the study
population. From January 2002 onward, ascertainment
was prospective. Suspected kala-azar cases were identified
through structured interviews by trained fieldworkers and
referred to the study physician for complete medical histo-
ry and physical examination. All seropositive persons were
also examined. We defined a past case of kala-azar as an
illness with >2 weeks of fever that resolved after 20 days
of intramuscular injections and included a history of 1 or
more of the following symptoms: weight loss, abdominal
fullness, abdominal pain, or skin darkening. Patients who
died with a disease consistent with kala-azar were also
included; several patients died during treatment. While
most patients could not identify the specific drug used, the
20-day course of injections corresponds to the sodium sti-
bogluconate (SSG) regimen prescribed as first-line treat-
ment by the national kala-azar management guidelines. We
defined current kala-azar cases based on history and phys-
ical examination (symptoms as for past cases, plus
splenomegaly or hepatomegaly, with or without measured
fever or jaundice) and positive serologic test results. To
confirm suspected kala-azar, we used the rK39 enzyme-
linked immunosorbent assay (ELISA) during serosurveys
and rK39 dipstick between serosurveys. The rK39 dipstick
(Inbios International, Seattle, WA, USA) is a rapid test for
kala-azar with very high sensitivity and moderately high
specificity (9,10).
All persons with active kala-azar were referred to the
Thana Health Complex located ≈1 km away. Patients with
an atypical presentation or suspected relapse were referred
to the district hospital for bone marrow aspiration and par-
asitologic confirmation. The study provided generic SSG
(GlaxoWellcome-Bangladesh); each batch was tested by
the International Dispensary Association (Amsterdam, the
Netherlands) to ensure pharmacologic quality. Because of
the ongoing SSG shortage in Bangladesh (8), the study
provided SSG for all new kala-azar patients in the commu-
nity, whether or not the patient lived in a study para.
Serologic Methods
Capillary blood specimens were collected from con-
senting participants >3 years of age. The serologic assay
used recombinant K39 antigen (Corixa Corporation,
Seattle WA, USA). In 2002, we used rK39 ELISAmethods
based on published protocols in which human antibodies
reacting with plate-bound L. donovani antigens were
detected with horseradish-conjugated protein A (11). The
positive cutoff was initially based on the mean optical den-
sity (OD) value of 4 wells of pooled negative control sera
plus 3 standard deviations as described previously (11).
Substantial plate-to-plate variation was seen in the nega-
tive control mean, and standard deviations were small;
positive cutoff OD values were often close to the negative
control mean. Therefore, to improve specificity for active
kala-azar case confirmation, we used an alternative cutoff
of 10 standard deviations (strong seropositive) for 2002
serosurvey data. We subsequently refined our methods to
address these issues. For 2003 and 2004 surveys, we
included a standard curve of dilutions of a pool of known
positive sera and based our cutoff on concentration units
from the standard curve for each plate (manuscript in
preparation). We also used horseradish peroxidase–conju-
gated goat anti-human immunoglobulin (Ig) G, IgA, and
IgM (Biosource International, Camarillo, CA, USA)
because this reagent yielded better specificity than protein
A conjugate. The negative cutoff was established by using
serum specimens from persons from areas of Bangladesh
not endemic for VL. Based on this assessment, we defined
an ELISA reading of >60 concentration units as strongly
seropositive.
Analytic Methods
All study households were mapped by Global
Positioning System, and data were uploaded into ArcView
Geographic Information System (GIS), v.3.3 (ESRI,
Redlands, CA, USA). By using GIS data, distance was cal-
culated from each household to the closest kala-azar case
in the preceding year, and for multivariable modeling, to
the closest case in any of the preceding years. To evaluate
the effect of cattle (cows, oxen, or calves) on kala-azar risk
for nearby residents, kernel density estimation was used to
estimate cattle per 1,000 m2. This index provides a
smoothed measure of both proximity and number of cattle.
Corresponding to where cattle were kept at night, the cat-
tle shed was considered the center of gravity. If the house-
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common practice of keeping cattle close to the house to
prevent theft. A 50-m cell size was used to weight the
analysis toward cattle in close proximity to a household,
regardless of ownership. 
Data were analyzed by using SAS 8.02 (SAS Institute
Inc, Cary, NC, USA). Univariate and multivariable models
were adjusted for within-household correlation by using
Generalized Estimating Equations. Multivariable models
were constructed by stepwise addition of variables signifi-
cant at the p = 0.05 level in univariate analyses.
Results
A total of 2,439 persons in 506 households met the
inclusion criteria. The surveyed population was 48% male
and 52% female; median age was 18 years (range 0–80).
Among those 20–29 years of age, 40% were male and 60%
female; some adult men worked in Dhaka or Mymensingh
and did not meet the inclusion criteria. For other age
groups, the sex distribution was similar. The median
household size was 5 persons (range 1–11).
During the 2002 serosurvey, 148 study participants had
a history of kala-azar treatment, and active kala-azar was
diagnosed in 16 patients. From the end of the 2002 survey
through April 2004, active kala-azar was diagnosed in 49
additional participants, for a total of 65 prospectively
ascertained kala-azar cases. In addition, probable relapses
were diagnosed in 3 previously treated kala-azar patients;
6 previously treated patients were diagnosed with
post–kala-azar dermal leishmaniasis. Altogether, we were
able to reliably assign status with respect to kala-azar for
2,356 (97%) of 2,439 persons, of whom 213 (9%) had
kala-azar or a history of kala-azar, 58 with onset before
2000 and 155 with onset in 2000 or later. Subsequent
analyses focused on the 155 kala-azar patients with onset
in 2000 or later because these data were considered the
most reliable and complete. 
The ELISA results were strongly positive for 33 (97%)
of 34 prospectively ascertained kala-azar patients tested;
the remaining patient had an ELISA reading of 57, just
below the cutoff of 60 concentration units. The other 31
prospectively ascertained kala-azar cases were confirmed
by rK39 dipstick (27 patients) or bone marrow aspirate (4
patients). Treated kala-azar patients also had strongly pos-
itive serologic test results that persisted for years after clin-
ical recovery; 13 (24%) of 54 patients treated in 2001 and
13 (50%) of 26 patients treated in 2002 remained seropos-
itive in 2004. Because so few patients had definitive para-
sitologic diagnosis, a formal analysis of serology
performance characteristics was not performed.
Para 1 had a higher cumulative incidence (77 [14%] of
540) than para 2 (39 [3%] of 1,221) or para 3 (39 [7%] of
537, p<0.01 for all three 2-way comparisons). Kala-azar
incidence peaked in 2001: 47 residents had illness onset in
2000, 57 in 2001, 23 in 2002, and 28 in 2003. No marked
seasonal pattern was apparent by onset month (Figure 1A).
Because ascertainment of cases with onset in 2003 was
incomplete at the time of analysis, we combined quarterly
data from January 2000 to December 2002 (Figure 1B).
The quarterly analysis showed a trend for more cases to
have onset from July to September and fewer cases from
January to March (goodness-of-fit χ2 = 5.63, p = 0.13).
The incidence was slightly higher in men than women
(p = 0.27) and was higher among children and young
adults than in the youngest and oldest age groups (p<0.01)
(Table 1). The median symptom duration before treatment
was 4.0 months. Among patients treated before the study
began, the duration was longer for female patients (5.0
months) than male patients (3.0 months, p = 0.09). After
we began active case finding, this trend disappeared (3.5
and 4.0 months for female and male patients, respectively,
p = 0.82). The case-fatality rate was 9% (14/155), 14%
among female patients and 5% among male patients (rela-
tive risk 2.7, p = 0.07).
From 2000 to 2003, kala-azar cases spread from a high-
ly clustered pattern to one in which substantial sections of
Kala-Azar Risk Factors, Bangladesh
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Figure 1. A) Kala-azar cases by symptom-onset month,
Bangladesh, January 2000 to August 2003. B) Kala-azar cases by
quarter of symptom onset, based on aggregated data, 2000-2002.
Ascertainment for cases with onset in 2003 was not complete at
the time of analysis. the study village were saturated (Figure 2). Kala-azar risk
was significantly higher among those living in the same
household as or within 50 m of a kala-azar patient in the
previous year (p = 0.0003 for closest patient in 1999 as pre-
dictor of kala-azar in 2000, p<0.0001 for closest patient in
2000 as predictor in 2001). By 2002, the pattern had dis-
seminated so that the difference in incidence based on prox-
imity was no longer significant in the overall study
population (p = 0.12). In 2000, 21% of the study population
lived within 50 m of a patient in the previous year; this fig-
ure rose to 37% in 2001 and 53% in 2002. When cumula-
tive incidence during the study period was considered, 72%
of the population lived within 50 m of a kala-azar case by
2003; in para 1, the proportion was 84% (Figure 2).
A number of other factors were associated with altered
kala-azar risk (Table 2). The risk of kala-azar was highest
for people in the 3- to 14-year and 15- to 45-year age
groups. Consistent use of a bed net, especially in summer,
was strongly protective (Table 2). The nets in use were not
treated with insecticide and were locally produced. Other
factors related to bed nets, such as net use in winter, house-
hold net ownership, and having >1 net per 3 household
members, were associated with weaker levels of protection
(Tables 2 and 3). Overall, 91% of households owned at
least 1 net, and 87% of participants reported sleeping
under a net at least some of the time. 
We examined the effect of both cattle ownership and
cattle density on kala-azar risk. Household cattle owner-
ship was associated with lower risk, but this finding did
not reach significance (p = 0.18, Table 3). However, the
kernel density analysis demonstrated a significant protec-
tive effect for increasing cattle density: the mean density
around the houses of persons without kala-azar was 1.4
cows/1,000 m2 compared to 1.1 cows/1,000 m2 for kala-
azar patients (odds ratio 0.75, 95% confidence interval
0.62–0.92, p = 0.005). A dose-response relationship was
seen; with 0 cows/1,000 m2 as the referent, <1 cow/1,000
m2 was associated with a 30% decrease, 1.1–2 cows/1,000
m2 with 40% decrease, and >2 cows/1,000 m2 with 43%
decrease in kala-azar risk.
No difference was seen in kala-azar risk by income,
education, or occupation; assets such as land, livestock,
farm implements, radio, or cart; housing materials and
condition; dietary intake of selected foods; keeping live-
RESEARCH
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Figure 2. Location of kala-azar patients
by year of symptom onset in para 1,
Bangladesh, 2000–2003.stock inside human sleeping rooms; or history of residual
insecticide spraying in the last 5 years (Tables 2 and 3). 
In the final multivariable model, 4 factors remained sig-
nificant. Age from 3 to 45 years and proximity to a previ-
ous patient increased kala-azar risk, while higher numbers
of cattle per 1,000 m2 and consistent use of a bed net in
summer were associated with protection (Table 4).
Discussion
This study is the first to examine spatial patterns and
risk factors for anthroponotic VL in Bangladesh. Although
we were not surprised that proximity to previous cases was
a determinant of subsequent kala-azar risk, the strength of
the association was remarkable. The 26-fold increase in
risk for those living with a patient reflects the role of active
kala-azar patients as the predominant infection reservoir.
In this study, the mean duration of illness before treatment
was 4 months; this delay provides ample opportunity for
sand flies that feed inside the house to become infected and
transmit disease. The risk associated with kala-azar
patients within 50 m but not farther may reflect the rela-
tively limited flight range of sand flies.
To present data applicable to regional control efforts,
we chose to focus our analysis on risk factors for kala-azar,
the form of VL reported in surveillance data and the pre-
dominant target of public health programs. In this analysis,
we did not distinguish between uninfected participants and
those with possible subclinical leishmanial infection. For
this reason, we may have underestimated the strength of
association for factors that alter risk of both leishmanial
Kala-Azar Risk Factors, Bangladesh
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control group. At the same time, factors that may alter the
risk of progression from infection to disease were not
examined. For example, immunogenetic factors play a role
in determining whether people infected with Leishmania
infantum (chagasi) progress to clinical disease (12).
Similar genetic factors are likely to affect progression of L.
donovani and may contribute to the household clustering
in our data. Poor nutritional status may also alter risk of
progression (13). Although our analysis showed no signif-
icant risk variation with socioeconomic or dietary indica-
tors, poor nutritional status may vary by household
resources and practices, contributing to the high risk for
members of kala-azar households.
Previous studies in South Asia demonstrated associa-
tions between kala-azar and poverty (14,15). However, the
facility-based survey in India and case-control study in
Nepal compared kala-azar patients to the general popula-
tion, whereas in the current analysis we studied a relative-
ly homogeneous, high-risk population. Our data showed
no differences in risk by occupation, income, housing type,
or assets aside from bed nets. Acommunity-based study of
kala-azar in India demonstrated an association with agri-
cultural occupation, but like our study, no association
between kala-azar and household income levels (16). The
primary occupation in the Indian village was weaving;
<10% of villagers were farmers. In contrast, 66% of our
population lived in agricultural households. The lack of
significance of socioeconomic factors may reflect the rela-
tive homogeneity of our study population and the fact that
at the community level, more proximate factors determine
kala-azar risk.
Our findings with respect to cattle answer a question
raised by the Nepal case-control study (15). In that study,
owning cattle or buffaloes conferred a strong protective
effect. However, because of the study design, it was
impossible to distinguish among 3 potential explanations
for this effect: socioeconomic confounding, better nutri-
tional status leading to decreased progression to kala-azar,
and the role of bovines as a preferred sand fly bloodmeal
source. The finding that cattle ownership was not as impor-
tant as cattle density strongly suggests that cows decrease
leishmaniasis transmission by sand flies in their immediate
vicinity. Sand fly bloodmeal analysis in India confirms that
Phlebotomus argentipes feed predominantly on bovines,
with humans as their second choice (17). The proximity of
cattle may diminish disease transmission by enabling sand
flies to feed preferentially on animals not susceptible to
RESEARCH
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sition, feeding on humans, or both. 
Remarkably, untreated, locally available bed nets were
associated with a 30% decrease in kala-azar risk in our
multivariable model. Because the usual incubation period
for kala-azar is 2–6 months (18), the strong protective
effect of net use in March–June and the higher kala-azar
incidence in the third quarter of the year are consistent
with high transmission in the Bangladeshi summer.
Nevertheless, some transmission probably occurs year-
round, except for December–January when almost no sand
flies are active. In addition, the extremes of the incubation
period are highly variable, with a reported range from 10
days to >2 years (18,19), making strict seasonal correlation
difficult. 
The protective effect of untreated nets in this analysis is
consistent with findings of the Nepal kala-azar case-con-
trol study (15). Intervention trials of insecticide-treated
materials for anthroponotic cutaneous leishmaniasis in
Afghanistan demonstrate strong protective efficacy (20),
and the high rate of use in our data suggests that bed nets
are already highly acceptable in VL-endemic communi-
ties. Indeed, at the community’s request, insecticide-treat-
ed nets were distributed to the population when the study
ended. These findings highlight the promise of insecticide-
treated nets as a VL control measure that could be imple-
mented and sustained through community action (8). Our
findings suggest that in VL-endemic areas where treated
nets are not yet available, untreated nets should be used
whenever possible.
The strong spatial clustering we found suggests that tar-
geted vector-control efforts, such as spraying to the most
affected foci, could be effective if they are instituted before
the transmission pattern generalizes. Furthermore, our data
suggest that generalization may occur within 2 to 3 years
when transmission is intense. Thus, rapidity of response
may be key to the success of a targeted intervention. The
several-year delays that commonly occur before spraying in
affected communities may help explain the low efficacy of
current targeted spraying programs in South Asia. The
incompleteness of kala-azar surveillance data may be
another factor. Nonetheless, better disease control might be
achieved through improved kala-azar surveillance systems
that integrate a rapid, targeted, vector-control response
mechanism. In addition, combining government-run spray-
ing programs with community-level efforts to increase
insecticide-treated net use could enhance vector control.
Maintenance of adequate kala-azar diagnostic and
treatment facilities at the peripheral level will also be
essential (8). Rapid diagnostic tests such as the rK39 dip-
stick and the direct agglutination test now make diagnos-
ing most kala-azar cases possible without invasive
procedures (21). Two new antileishmanial drugs, miltefos-
ine and paromomycin, are or soon will be available in
India, where antimonial drug resistance presents a major
challenge to control (22). Both have advantages over cur-
rently used antileishmanial drugs, miltefosine because of
its oral administration and paromomycin because of its
excellent safety profile. The low rate of relapse in our
study suggests that most VL in Bangladesh is still respon-
sive to SSG. Nevertheless, if miltefosine and paromomycin
can be made available in Bangladesh and Nepal at afford-
able prices, treatment could be made simpler and more
effective. The resurgence of kala-azar in South Asia since
1990 has raised policymakers’awareness of this historical-
ly neglected disease, which suggests that the political will
may finally exist to address VLin a concerted fashion (23).
The time has come to mount an aggressive, integrated
effort to control anthroponotic visceral leishmaniasis.
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